HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $36

Benzinga · 2d ago
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $38 to $36.